Nile , BelgiumAnd 27 July 2021 /PRNewswire/ — eTheRNA immunotherapies NV (“eTheRNA” or “the Company”), a clinical-stage company developing mRNA-based immunotherapies to treat cancer and infectious diseases, today announced the appointment of Matthew Lin As Chief Financial Officer and President of eTheRNA Inc. , a newly incorporated subsidiary of it in the United States.
Matthew Lin He brings a riches of experience in the pharmaceutical and biotechnology industry. Served over 15 years in investment banking in the healthcare industry New York, working on a wide range of financing and strategic transactions for both big pharmaceutical companies and emerging biopharma companies. He was most recently at Guggenheim Securities and prior that at Bear Stearns. Organic chemist by training, Mathieu has also worked in lipid-based gene therapy research at Genzyme and in venture capital at SR One. It will be based in the unused office of eTheRNA in New York.
Stephen PowelleTheRNA CEO said: “We are delighted to welcome Matthew to eTheRNA as we look to maximize the potential of mRNA and related technology platforms. Mathieu is a key addition to our senior leadership team and will play an significant role in managing coming funding strategies and establishing our presence in the North America. Today’s announcement is an significant step in the development and growth of our company as we look to strengthen our position in key geographies and accelerate the development of our technology and product pipeline.”
Matthew LineTheRNA CFO commented: “Over the former year, we have seen the aptitude of mRNA technology to generate unused and effective therapies. eTheRNA has a powerful next-generation mRNA platform that offers tremendous potential for developing ready-made treatments for cancer, infectious diseases and, potentially, autoimmune disorders. This exciting time as we look forward to making our mark in United States of America and maximizing the potential of eTheRNA technologies and the product pipeline.”
eTheRNA is headquartered in Neal, Belgium and the facility of his discovery in Ghent, Belgium.
About eTheRNA Immunotherapy
eTheRNA Immuno develops immunotherapy products and vaccines for the treatment of cancer, infectious diseases, and autoimmune disorders from multiple RNA platforms, formulating and manufacturing technology. The head office of the company is located in BelgiumLtd., with an office in the United States, and was incorporated in 2013. Its founding shareholders include Progress Pharma and VUB eTheRNA is backed by an international group of dedicated investors: BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund +, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the company’s ambition to build a world-leading RNA company. To date, the company has raised 63 million euros in project financing. More details regarding eTheRNA can be found at www.etherna.be
View original content: https://www.prnewswire.com/news-releases/etherna-immunotherapies-appoints-mathieu-lane-as-chief-financial-officer-and-president-of-etherna-inc-located-in- the-usa-301341302.html